Table 3.
Adjusted mean (SE) change from baseline in body weight (kg) at weeks 12 and 24 with vildagliptin 50 mg qd/bid and placebo by racial/ethnic subgroups
| Race/ethnicity | Adjusted mean change from baseline, Week 12 | Adjusted mean change from baseline, Week 24 | ||||||
|---|---|---|---|---|---|---|---|---|
| Vildagliptin | Vildagliptin | Placebo | Placebo | Vildagliptin | Vildagliptin | Placebo | Placebo | |
| n | 50 mg qd/bid | n | n | 50 mg qd/bid | n | |||
| Caucasians | 1317 | 0.15 (0.06) | 890 | −0.32 (0.06) | 1280 | 0.28 (0.07) | 842 | −0.34 (0.08) |
| Asians | 1097 | 0.03 (0.06) | 879 | −0.36 (0.07) | 786 | 0.04 (0.09) | 603 | −0.44 (0.10) |
| Japanese | 274 | 0.47 (0.11) | 222 | −0.33 (0.12) | N/A 1 | |||
| Chinese | 543 | −0.29 (0.08) | 411 | −0.44 (0.10) | 519 | −0.13 (0.11) | 375 | −0.55 (0.12) |
| Indian | 210 | 0.01 (0.14) | 185 | −0.26 (0.15) | 202 | 0.21 (0.17) | 170 | −0.27 (0.19) |
All values are expressed as mean (SE) unless specified. P‐value for interaction term at week 12 = 0.6245, and at week 24 = 0.3550.
Abbreviations: bid, twice daily; qd, once daily; N/A, not available; SE, standard error.
1
All Japanese studies were of 12‐weeks duration.